Drug Trial Radar · NCT07896005
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
436
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Feb 2031
Study completion Mar 2032
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as first-line treatment in patients with HER2-overexpressing locally advanced or metastatic non-squamous non-small cell lung cancer.
Conditions
- Non Small Cell Lung Cancer
Interventions
SHR-A1811 InjectionDrug
SHR-A1811 Injection.
Adebrelimab InjectionDrug
Adebrelimab Injection.
Tislelizumab InjectionDrug
Tislelizumab Injection.
Pemetrexed Disodium For InjectionDrug
Pemetrexed Disodium For Injection.
Carboplatin injectionDrug
Carboplatin Injection.
Cisplatin injectionDrug
Cisplatin Injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) based on blinded independent central review (BICR)Time frame: From randomization until disease progression or death from any cause, whichever occurs first, up to approximately 40 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.